Pediatric psoriasis induced by HLA‐B46‐Cw1 haplotype: A retrospective study of psoriasis onset after hematopoietic stem cell transplantation

Abstract

Psoriasis is a chronic inflammatory skin disease characterized by raised, well-demarcated, erythematous plaques and can significantly impair a patient's quality of life. 1,2 Recent advances in genetic analysis technology have revealed the contribution of the HLA-C locus to psoriasis. 3,4 Along with loci relating to the major histocompatibility complex (MHC), genome-wide association studies (GWAS) for psoriasis and psoriatic arthritis have revealed loci relating to immunological genes. Thus, psoriasis develops on the background of susceptibility to immunological challenges. Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic tumors and immunodeficiency diseases. HLA mismatch transplantations are occasionally performed and can result in HLA haplotype changes after transplantation. Given that the HLA loci are associated with the genetic background of psoriasis, there is a possibility that psoriasis may be induced or exacerbated if this change in HLA haplotypes occurs. In this study, we retrospectively investigated 378 pediatric patients who had undergone HSCT and

Body mass index, HbA1c and serum C‐reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital‐based retrospective case‐control study

“…The genetic backgrounds including HLA were not assessed. 20 There were no data of serum level of TNF and of anti-IFX antibody to speculate the reason of the secondary failure. The 1-year IFX drug survival, which included the discontinuation of secondary failure and side effects, was 79.41% in this study (data not shown).…”